



Pharmaceutical Nanotechnology

# Loading of curcumin into macrophages using lipid-based nanoparticles

Keitaro Sou, Shunsuke Inenaga, Shinji Takeoka, Eishun Tsuchida \*

*Advanced Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan*

Received 3 July 2007; received in revised form 28 August 2007; accepted 21 October 2007

Available online 1 November 2007

## Abstract

Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, Cm) is a natural compound which possesses antioxidant, anti-inflammatory and anti-tumor ability. Here, phospholipid vesicles or lipid-nanospheres embedding Cm (CmVe or CmLn) were formulated to deliver Cm into tissue macrophages through intravenous injection. Cm could be solubilized in hydrophobic regions of these particles to form nanoparticle dispersions, and these formulations showed ability to scavenge reactive oxygen species as antioxidants in dispersions. At 6 h after intravenous injection in rats via the tail vein (2 mg Cm/kg bw), confocal microscopic observations of tissue sections showed that Cm was massively distributed in cells assumed as macrophages into the bone marrow and spleen. Taken together, these results indicate that the lipid-based nanoparticles provide improved intravenous delivery of Cm to tissues macrophages, specifically bone marrow and splenic macrophages in present formulation, which has therapeutic potential as an antioxidant and anti-inflammatory.

© 2007 Elsevier B.V. All rights reserved.

**Keywords:** Nanoparticles; Liposomes; Bone marrow; Macrophage; Antioxidant; Drug delivery

## 1. Introduction

Because of the significant phagocytic ability of the mononuclear phagocyte system (MPS) to nanoparticles *in vivo*, drug delivery which targets macrophages can be reasonably achieved by using nanoparticles. Recent studies indicated that macrophages relate with various diseases associated with inflammation and the macrophage targeting may open new therapeutic approaches for controlling the diseases (Chellat et al., 2005; Zeisberger et al., 2006; Schmid and Varner, 2007).

Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, Cm) (Fig. 1) is a natural compound isolated from the root of *Curcuma longa* that has been shown to exhibit antioxidant, anti-inflammatory and anti-tumor abilities (Kunchandy and Rao, 1990; Singh and Aggarwal, 1995; Kuo et al., 1996; Shishodia et al., 2005; Sharma et al., 2005). Cm has been demonstrated to have scavenger ability against reactive oxygen species (ROS), such as superoxide anion ( $O_2^{\bullet-}$ ),

hydrogen peroxide ( $H_2O_2$ ) and nitric oxide (NO), both *in vitro* and *in vivo* (Kunchandy and Rao, 1990). In addition, it has been reported to be a potent inducer of heme oxygenase-1 in vascular endothelial cells (Mottlerlini et al., 2000). These properties contribute to the protection of cells and tissue from oxidative stress. Further, anti-inflammatory ability of Cm is induced by the suppression of nuclear factor-kappa B (NF- $\kappa$ B) activation, which results in the inhibition of synthesis of inducible nitric oxide synthase (iNOS) in macrophages (Pan et al., 2000). Thus, macrophages can be a therapeutic targeted cellular component for Cm.

Oral Cm administration as a cancer therapy in phase I clinical studies in humans produced minimal side effects (Cheng et al., 2001; Sharma et al., 2004). However, the clinical pharmacokinetics studies revealed maximum Cm plasma levels in the range of only 1.8–11 nM in patients, even for oral administration of several grams of Cm per day. Thus, the current conclusion on Cm is that it has poor bioavailability when orally administered. This unsatisfactory pharmacokinetics of oral administration is not restricted to Cm, but is also observed for various lipophilic drug candidates.

A promising approach to developing improved delivery systems lipophilic drugs employs lipid-based carriers such as

\* Corresponding author. Tel.: +813 5286 3120; fax: +813 3205 4740.

E-mail addresses: [ksou@waseda.jp](mailto:ksou@waseda.jp) (K. Sou), [eishun@waseda.jp](mailto:eishun@waseda.jp) (E. Tsuchida).




Fig. 1. Structure of curcumin. This compound is insoluble in water because of strong hydrophobicity of diketo moiety.

micelles, vesicles (liposomes), and nano- or microspheres, which can solubilize lipophilic drugs in self-assembling processes. Cm is known to interact with phospholipids or surfactants to solubilize in aqueous dispersions (Began et al., 1999; Tønnesen, 2002; Bruzell et al., 2005). Recently, some investigators have advanced this research to incorporate complexes of Cm with phospholipids in drug delivery systems (Li et al., 2005; Kunwar et al., 2006; Maiti et al., 2007). In immunohistochemical studies, Li et al. observed antiangiogenesis effect following intravenous injection of Cm-liposomes, which suppressed pancreatic carcinoma growth in murine xenograft models (Li et al., 2005). More recently, Maiti et al. reported that intraperitoneal injection of Cm–phospholipid complex has better hepatoprotective activity, owe to its superior antioxidant property, than free Cm (Maiti et al., 2007). These reports indicated that the therapeutic potential of Cm would be enhanced by the development of efficient drug delivery system.

Recently, we found that surface modification of vesicles with L-glutamic acid, *N*-(3-carboxy-1-oxopropyl)-, 1,5-dihexadecyl ester (SA) and poly(ethylene glycol) (PEG)-lipid increases the distribution of vesicles into bone marrow macrophage when injected in small doses (Sou et al., 2007). This finding is applied for the intravenous delivery of Cm to tissue macrophages in this study. Here, nano-sized vesicles containing Cm (CmVe) and lipid-nanospheres (CmLn) were prepared and characterized. Furthermore, distribution of Cm in organs after intravenous injection in rats was observed. We show that these nanoparticle systems would be available to deliver Cm to tissues macrophages, specifically bone marrow and splenic macrophages in present system.

## 2. Materials and methods

### 2.1. Materials

1,2-Dimyristoyl-*sn*-glycero-3-phosphocholine (DMPC) and L-glutamic acid, *N*-(3-carboxy-1-oxopropyl)-, 1,5-dihexadecyl ester (SA) were purchased from Nippon Fine Chemical Co. Ltd. (Osaka, Japan); 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine-*N*-[monomethoxy poly(ethylene glycol) (5000)] (PEG-DSPE) was purchased from NOF Co. (Tokyo, Japan). Soybean oil was purchased from Kanto Chemical Co. (Tokyo, Japan). Curcumin (Cm) was purchased from SIGMA (St. Louis, MO, USA). 8-Amino-5-chloro-7-phenylpyrid[3,4-*d*]pyridazine-1,4-(2H,3H) dione sodium salt (L-012), hypoxanthine, xanthine oxidase, and superoxide dismutase (SOD, 3400 U/mg), were purchased from Wako Pure Chemical Industries (Tokyo, Japan).

### 2.2. Preparation of CmVe

Lipid powder of DMPC/SA/PEG-DSPE (10/1/0.06, molar ratio) and Cm were dissolved in the mixed solvent system of *t*-butyl alcohol and benzene (1/1, v/v) and then lyophilized to obtain mixed lipid powder containing Cm. The lyophilized powder was hydrated in physiological saline at 70 mg mL<sup>-1</sup> for 30 min under stirring by a vortex mixer. The dispersion was subjected to extrusion (final pore size of the filter: 0.2 μm, Isopore®, Millipore, Tokyo, Japan) and finally filtered through sterilized filters (pore size: 0.2 μm Dismic, Toyo Roshi, Tokyo, Japan) to obtain fine-sized Cm-vesicles (CmVe). Sample preparation for animal experiment was performed under sterilized conditions.

### 2.3. Preparation of CmLn

To prepare the Cm lipid-nanosphere formulation (CmLn), Cm was dissolved in soybean oil (10 mg mL<sup>-1</sup>) at 150 °C, and then mixed with lipid powder comprising DMPC/SA/PEG-DSPE (10/1/0.06, molar ratio) dissolved in soybean oil (280 mg mL<sup>-1</sup>) at 60 °C. This mixed solution was introduced into 2.5% glycerin solution under vigorously stirring with a wing stirrer (1200 rpm) and continuously stirred for 30 min to obtain crude lipid-microsphere dispersion. The dispersion was subjected to extrusion to control the size of the lipid-nanosphere (final pore size of the filter: 0.2 μm, Isopore®, Millipore, Tokyo, Japan) and finally passed through sterilized filters (pore size: 0.2 μm Dismic, Toyo Roshi, Tokyo, Japan) to obtain CmLn. Sample preparation for animal experiment was performed under sterilized conditions.

### 2.4. Characterization of CmVe and CmLn

The concentration of Cm in CmVe and CmLn was determined from calibration curves of absorbance at 420 nm prepared in ethanol, and the concentration of phospholipid was determined using a phospholipid assay kit (Phospholipid C Test Wako, Wako Pure Chemical, Tokyo Japan). The diameter of the resulting CmVe and CmLn was determined with a COULTER submicron particle analyzer (N4SD, Coulter, Hialeah, FL), and represented as an average diameter ± standard deviation (S.D.). The zeta(ζ)-potential was determined with a Zeta-Sizer Nano ZS (Malvern, MA, USA). Florescence imaging was carried out with excitation at 488 nm on a confocal scanning microscope (Olympus IX70, Tokyo, Japan) equipped with an ArKr ion laser system (Yokogawa) and recorded with image analysis software (IPLab version 3.5 for Macintosh, Scanalytics, Inc., VA, USA). Transmission electron microscopy (TEM) was carried out using a negative staining technique. Briefly, equivolumes of the sample and 2% phosphotungstic acid solution were mixed, and then a drop of mixed solution was allowed to settle on a carbon-coated copper grid for 1 min. Excess sample was removed by filter paper, dried in a desiccator, and visualized using a JEOL JEM-1011/100 kV (JEOL, Tokyo Japan).

## 2.5. Chemiluminescence assay

ROS scavenge ability of CmVe was evaluated by the generation of  $O_2^{\bullet-}$  in a hypoxanthine and xanthine oxidase system. L-012 ( $50 \mu\text{M}$ ) was used for chemiluminescence probe to detect  $O_2^{\bullet-}$  according to Nishinaka et al. (1993). Xanthine oxidase, L-012, and CmVe were mixed together in test tube and  $O_2^{\bullet-}$  generation was started by the addition of hypoxanthine. The final concentrations of reagents were fixed at hypoxanthine,  $0.5 \text{ mM}$ ; xanthine oxidase,  $25 \text{ mU/mL}$ ; and L-120,  $50 \mu\text{M}$ ; CmVe was supplied in the concentration range  $1\text{--}100 \mu\text{M}$ . Chemiluminescence was counted for 3 min after addition of hypoxanthine using an AccuFLEX Lumi400 from ALOKA (Tokyo, Japan). Ve, having the same lipid concentration with CmVe, was tested with the same procedure to determine the effect of lipid components. In addition, SOD, which is a popular  $O_2^{\bullet-}$  scavenger, was tested with the same procedure to serve as a reference for the  $O_2^{\bullet-}$  scavenging ability.

## 2.6. Animal experiments

Animal experiments were performed under the regulations for Animal Experimentation at Waseda University and were approved by the Steering Committee for Animal Experimentation at Waseda University. Male Wister rats ( $200\text{--}218 \text{ g}$ ) were anesthetized with 2% isoflurane (VedCo, St Joseph, MO, USA) in 100% oxygen gas. Samples were injected into the tail vein at  $1 \text{ mL/min}$ . Each rat received a total dose of Cm:  $2 \text{ mg/kg}$  as dispersion of CmVe or CmLn ( $n=5$ ). The blood sample was collected just before injection, and various time after injection to monitor the circulation level of blood cells. At 6 h after injection, the animals were scarified to collect bone marrow, liver, and




Fig. 2. Solubilization capacity of DMPC-vesicles for curcumin.

spleen. The organs were fixed in 10% formaldehyde, sectioned, fixed on glass slides with 2% agar solution, and observed under a confocal scanning microscope (Olympus IX-70).

## 3. Results

### 3.1. Preparation and characterization of CmVe

All DMPC, SA, PEG-DSPE, and Cm compounds were successfully dissolved in mixed solvent of *t*-butyl alcohol and benzene (1/1, volume ratio) and the lyophilized powder was employed for the preparation of vesicles. Initially, we applied various amounts of Cm in order to determine the maximum capacity of vesicles to stably immobilize the Cm. As shown in Fig. 2, when the weight ratio of Cm to DMPC was below 0.1, vesicles could completely solubilize the Cm in dispersion of vesicles. When the weight ratio of employed Cm in the origi-




Fig. 3. Structural characterization of (A) DMPC-vesicles comprising curcumin (CmVe) and (B) lipid-nanosphere comprising curcumin (CmLn). Confocal scanning microscopic images (left) and transmission electron micrographs (TEM) (right) of CmVe and CmLn. Confocal scanning microscopic images were taken before extrusion to submicron size to enable observation of the structure within resolution of a confocal microscope. These images indicate the localization of Cm in vesicles and lipid-sphere with diameter of ca.  $10 \mu\text{m}$ . Bars in TEM represent  $100 \text{ nm}$ . Illustrations are estimated structures of CmVe and CmLn.

Table 1  
Diameter and  $\zeta$ -potential of CmVe and CmLn with and without SA

Particle type	Composition of lipids (molar ratio)	Diameter (nm)	$\zeta$ -potential <sup>a</sup> (mV)
CmVe	DMPC/PEG-DSPE (10/0.06)	193 ± 75	-1.99 ± 1.86
	DMPC/SA/PEG-DSPE (10/1/0.06)	187 ± 53	-21.1 ± 1.88
CmLn	DMPC/PEG-DSPE (10/0.06)	219 ± 95	0.018 ± 1.95
	DMPC/SA/PEG-DSPE (10/1/0.06)	217 ± 93	-19.8 ± 0.28

<sup>a</sup>  $\zeta$ -potential was measured in 10 mM phosphate buffer solution (pH 7.4, NaCl 20 mM).

nal powder was increased above 0.1, an excess fraction of Cm formed an orange solid in dispersion medium during hydration. To control the size of vesicles resulting in the decreasing of solubilized ratio of Cm, the solid Cm was filtrated out in the subsequent extrusion procedure. Therefore, we determined that the capacity of the present vesicles to stably solubilize Cm was 0.1 in weight ratio of Cm to DMPC, a value which is equivalent to 16 mol% Cm in the DMPC membrane. Thus, we determined the stable formulation of vesicles solubilizing Cm in their bilayer membrane to be DMPC/SA/PEG-DSPE/Cm (10/1/0.06/1.9, molar ratio), which is applied for the following experiments as CmVe. We confirmed that 97% of Cm was present in CmVe fraction separated by ultracentrifugation, indicating that little Cm was isolated from Ve in prepared dispersion.

Confocal scanning microscopic observation indicated that the Cm was located in the membrane of vesicles, but not in the inner aqueous phase, while TEM observation showed that the CmVe have an origolamellar structure, which is typically comprised of three to six layers. One representative vesicle is shown in Fig. 3A. The  $\zeta$ -potential of CmVe was determined to be  $-21.1 \pm 1.88$  mV at pH 7.4 and its diameter was  $187 \pm 53$  nm (Table 1). This data showed that the CmVe is a nano-sized anionic particle. The  $\zeta$ -potential of vesicle prepared without SA was  $-1.99 \pm 1.86$  mV, indicating that the incorporation of SA results in an anionic surface. Based on these results, we estimated the structure of CmVe as illustrated in Fig. 3A, where PEG and SA express their physicochemical characters on the surface of CmVe, and Cm locates in the multilayer bilayer

membrane. Spectroscopic data further indicate that the location of Cm is in the bilayer membrane. As shown in Fig. 4A, the spectra of CmVe dispersion showed a peak with three compartments. The  $\lambda_{\max}$  was observed at 401 nm at 10 °C, where the dispersion was orange rather than yellow. With increasing temperature, the peak at 401 nm decreased and the peak at 420 nm increased to where the color of dispersion changed to yellow. Plotting the absorbance at 420 nm by temperature showed that the absorbance of 420 nm was critically increased between 20 and 30 °C (Fig. 4B). This range corresponded to the gel–liquid crystalline phase transition temperature of DMPC (23 °C) (Pownall et al., 1977), suggesting that the molecular state of Cm is influenced by the phase state of the bilayer membrane. This observation also supported by the fact that Cm is located in the bilayer membrane.

### 3.2. Preparation and characterization of CmLn

Regarding the preparation of CmLn, the solubility of the Cm in soybean oil was limited to the maximum solubilization of Cm, which has a solubility of approximately  $10 \text{ mg mL}^{-1}$  at preparation condition (around 25 °C). The same lipid formulation with CmVe [DMPC/SA/PEG-DSPE (10/1/0.06, molar ratio)] was applied for CmLn. The soybean oil solution was injected into 2.5% glycerin solution under stirring. Subsequently, the dispersion was passed through a membrane filter to control the size of CmLn. The incorporation of SA contributed to the anionic surface of CmLn ( $\zeta$ -potential:  $-19.8$  mV) indicating that the anionic head group of SA is located on the surface of the CmLn




Fig. 4. Spectral property of CmVe dispersion with temperature. (A) Raw spectra at 10, 25, and 40 °C. (B) Absorbance at 420 nm plotted according to temperature. Absorbance of Cm critically changes in range of the gel–liquid crystalline phase transition temperature ( $T_c$ , 23 °C) of DMPC membrane, indicating that Cm is embedded in membrane.




Fig. 5. Scavenging superoxide anion ( $O_2^{\bullet-}$ ) by CmVe as a function of concentration of Cm.  $O_2^{\bullet-}$  was produced by hypoxanthine (0.5 mM) and xanthine oxidase (25 mU/mL) system and detected by a chemiluminescence probe L-120 (50  $\mu$ M). Vesicles without Cm (Ve) are being used as a control. Small panel shows the comparable experiment with SOD.

(Table 1). Confocal scanning microscopic observation indicated that the Cm was located inside the oil phase of Lm, while TEM observation indicated a spherical shape without an inner aqueous phase (Fig. 3B). Based on dynamic light scattering measurement, the diameter of CmLn was determined to be  $217 \pm 93$  nm in dispersion state (Table 1).

### 3.3. ROS scavenge ability

As shown in Fig. 5, depending on the concentration of Cm, CmVe showed the ability to scavenge generated  $O_2^{\bullet-}$  from hypoxanthine and xanthine oxidase system. Based on these data, we determined that the concentration of CmVe required to reduce 50% of chemiluminescence of L-012 by  $O_2^{\bullet-}$  was 1.8, and 25  $\mu$ M is required to reduce 90% of chemiluminescence of L-012 by  $O_2^{\bullet-}$ , as summarized in Table 2. As comparative index of  $O_2^{\bullet-}$  scavenging ability, SOD which ability was defined as unit, was applied in the same  $O_2^{\bullet-}$  generation system. As shown in the small panel in Fig. 5 and in Table 2, 160 units/L SOD reduced 50% of chemiluminescence of L-012, and 1050 units/L SOD reduced 90% of chemiluminescence of L-012. Thus, we roughly estimated that the  $O_2^{\bullet-}$  scavenger ability in 1.8–25  $\mu$ mol range of Cm in present formulation of CmVe was comparable to the 160–1050 range of SOD units. DMPC vesicles that consisted of saturated phospholipids and saturated SA were not reactive

Table 2  
Scavenger ability of CmVe or vesicles without Cm (Ve) to superoxide anion ( $O_2^{\bullet-}$ ) generated from hypoxanthine and xanthine oxidase system

Scavengers	IC <sub>50</sub> <sup>a</sup>	IC <sub>90</sub> <sup>a</sup>
CmVe	1.8 $\mu$ M	25 $\mu$ M
Ve	na	na
SOD	160 units/L	1050 units/L

<sup>a</sup> IC<sub>50</sub> and IC<sub>90</sub> are concentration of Cm to scavenge 50 and 90% of  $O_2^{\bullet-}$  (na = not active).




Fig. 6. Profiles of blood cell counts after intravenous infusion of (A) CmVe dispersion or (B) CmLn dispersion in rats. Each rat received 2 mg Cm/kg bw. Percentages are blood cell counts before injection of sample. WBC: white blood cells, PLT: platelets, RBC: Red blood cells.

to  $O_2^{\bullet-}$ . These data indicate that the present nanoparticulate formulations potentially have ROS scavenger ability.

### 3.4. Intravenous delivery and distribution in organs

Prepared CmVe or CmLn with SA were intravenously injected in rats to monitor the injection response of blood cells and observe organ distribution. All rats ( $n = 5$ ) received CmVe or CmLn were survived for 6 h after injection. As shown in Fig. 6, no acute response to injection of these formulations was observed in circulating blood cells. In rats receiving CmVe or CmLn, white blood cells (WBC) tended to gradually decrease to  $89 \pm 8$  or  $84 \pm 13\%$  until 1 h, and then returned to baseline levels. Upper recovery to baseline levels was observed in CmVe at 6 h, but was not observed in CmLn. As for red blood cells (RBC) and platelets (PLT), the circulating level tended to decrease in a similar manner until 3 h, and then returned to baseline. At 6 h, bone marrow, liver, and spleen samples were collected for observation of the distribution of Cm in these tissues. As shown in Fig. 7, confocal scanning microscopy indicated that the Cm emitting yellow fluorescence was located in these tissues. This observation indicated intravenous injection of Cm using present lipid-based nanoparticles could facilitate the delivery of Cm into macrophages especially in bone marrow and spleen.




Fig. 7. Confocal scanning images of bone marrow, spleen, and liver collected from rat that received CmVe or CmLn dispersion (2 mg Cm/kg bw) 6 h after intravenous infusion. Yellow fluorescence indicates the distribution of Cm in organs.

#### 4. Discussion

As Cm is a water-insoluble compound, Cm is conventionally administered orally, which has low bioavailability. The present study offered stable intravenous formulations using lipid-based nanoparticles. The binding constant for the interaction of Cm with egg and soy phosphatidylcholine was reported to be  $3.26 \times 10^5$  and  $2.64 \times 10^5 \text{ M}^{-1}$ , respectively (Began et al., 1999), and that of phosphatidylcholine liposomes containing cholesterol was  $2.5 \times 10^4 \text{ M}^{-1}$  (Kunwar et al., 2006). In our preliminary examination to determine the components of the bilayer membrane, vesicles that consisted of 1,2-dipalmitoyl-*sn*-glycero-3-phosphocholine and cholesterol (1/1, molar ratio) could solubilize much less Cm in bilayer membrane (below 3 wt.% of Cm to lipids) than DMPC vesicles, and the mixing examination of each component indicated that the low affinity of Cm to cholesterol causes the low solubilized capacity of bilayer membrane containing cholesterol (data not shown). Thus, we used DMPC without cholesterol to stably solubilize Cm. It has been reported that six molecules of phosphatidylcholine could bind one molecule of Cm (Began et al., 1999). As shown in Fig. 2, the maximum solubilization capacity of DMPC to Cm was determined to be approximately 10 wt.% and it was calculated that one Cm was fixed by 5.4 molecules of DMPC. These data are consistent with previous report (Began et al., 1999). In terms of preparation techniques, it should be considered that excess Cm formed solid precipitate which could be removed by filtration; however, as shown in Fig. 2, too much excess Cm decreased the solubilized amount of Cm. In the case of CmLn, the solubilization of Cm in employed oil was a factor for determining the maximum Cm content. Present soybean oil could solubilize Cm at approximately  $10 \text{ mg mL}^{-1}$  in preparation conditions.

Confocal scanning microscopic observation clearly indicated that Cm was solubilized in the bilayer membrane of vesicles or

the inner oil phase of lipid-nanosphere in the present preparation procedure. TEM observation showed the oligolamellar membrane structure of CmVe (Fig. 3A). The spectroscopic analysis also indicated that the location of Cm is in the bilayer membrane (Fig. 4). In contrast, we could not find lamellar membrane structure in CmLn (Fig. 3B).  $\zeta$ -potential measurement indicated that the carboxyl group of SA is located on the surface to characterize the surface with anion (Table 1). Thus, we identified two kinds of characterized anionic particles solubilizing Cm in their hydrophobic region as CmVe and CmLn. We have identified that surface modification of phospholipid vesicles with two compounds, SA and PEG-DSPE, cooperatively increases the distribution of vesicles into bone marrow macrophages (Sou et al., 2007).

As a therapeutic potential, CmVe showed scavenger ability against the ROS in several  $\mu\text{M}$  ranges (Fig. 5 and Table 2). It has been suggested that Cm is a potent agent for the suppression of septic or hemorrhagic organ failure (Lukita-Atmadja et al., 2002; Madan and Ghosh, 2003; Kaur et al., 2006; Siddiqui et al., 2006). Macrophages are target cells in such inflammation because they produce various mediators such as cytokines and ROS that promote inflammation following oxidative damage. Therefore, we were interested in the distribution of Cm in organs, in which the fluorescence of Cm was useful to detect the Cm in organs as shown in Fig. 7. At 6 h after injection, organ distribution of Cm in the present particulate system clearly indicated that the cellular components assumed to be macrophages are responsible for the uptake, especially in bone marrow and spleen. The competition of splenic uptake to bone marrow uptake would be more significant in rat model than that in previous pharmacokinetic study of vesicles containing SA in a rabbit model, because the rat spleen has about nine times larger capacity for uptake of vesicles compared with rabbit spleen (Sou et al., 2005, 2007). In liver, the relative high background fluorescence might

be due to the diffuse distribution of Cm. It is known that albumin can bind Cm when the binding constant is in the  $10^4$ – $10^5$  M<sup>-1</sup> range (Kunwar et al., 2006; Pulla Reddy et al., 1999; Barik et al., 2003). As this binding constant of albumin to Cm is equal to that of phospholipids, it is speculated that a fraction of Cm might be transferred from vesicles to serum albumin. The cellular uptake was not obvious in liver. Further pharmacokinetic study is necessary in order to determine the quantitative distribution of Cm in whole body. In present study, we indicated that the loading of Cm into tissue macrophages, mainly bone marrow and splenic macrophages, could be achieved in rats. In addition to the ROS scavenger ability, this system can be expected to efficiently suppress the NF- $\kappa$ B activation to inhibit the synthesis of iNOS in macrophages (Pan et al., 2000). These events should be a therapeutic benefit for treatment with oxidative injury and inflammation.

## 5. Conclusions

Two nanoparticles embedding Cm have been offered for intravenous injection of Cm. These nanoparticulate formulations could deliver Cm into tissue macrophages, specifically bone marrow and splenic macrophages in rats. This intravenous delivery system of Cm using lipid-based nanoparticles may be available for antioxidant and anti-inflammatory therapies.

## Acknowledgements

This work was partly supported by the Japanese Ministry of Education, Culture, Sports, Science and Technology, through a Grant-in-Aid for Scientific Research (B) (17300162, 2005). The authors gratefully acknowledge Dr. William T. Phillips and Dr. Beth Goins (UTHSCSA) for suggestion and discussion for this research.

## References

- Barik, A., Priyadarsini, K.I., Mohan, H., 2003. Photophysical studies on binding of curcumin to bovine serum albumin. *Photochem. Photobiol.* 7, 597–603.
- Began, G., Sudharshan, E., Udaya Sankar, K., Appu Rao, A.G., 1999. Interaction of curcumin with phosphatidylcholine: a spectrofluorimetric study. *J. Agric. Food Chem.* 47, 4992–4997.
- Bruzell, E.M., Morisbak, E., Tønnesen, H.H., 2005. Studies on curcumin and curcuminoids. XXIX. Photoinduced cytotoxicity of curcumin in selected aqueous preparations. *Photochem. Photobiol. Sci.* 4, 523–530.
- Chellat, F., Merhi, Y., Moreau, A., Yahia, L.H., 2005. Therapeutic potential of nanoparticulate systems for macrophage targeting. *Biomaterials* 26, 7260–7275.
- Cheng, A.L., Hsu, C.H., Lin, J.K., Hsu, M.M., Ho, Y.F., Shen, T.S., Ko, J.Y., Lin, J.T., Lin, B.R., Ming-Shiang, W., Yu, H.S., Jee, S.H., Chen, G.S., Chen, T.M., Chen, C.A., Lai, M.K., Pu, Y.S., Pan, M.H., Wang, Y.J., Tsai, C.C., Hsieh, C.Y., 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Res.* 21, 2895–2900.
- Kaur, G., Tirkey, N., Bharrhan, S., Chanana, V., Rishi, P., Chopra, K., 2006. Inhibition of oxidative stress and cytokine activity by curcumin in amelioration of endotoxin-induced experimental hepatotoxicity in rodents. *Clin. Exp. Immunol.* 145, 313–321.
- Kunchandy, E., Rao, M.N.A., 1990. Oxygen radical scavenging activity of curcumin. *Int. J. Pharm.* 58, 237–240.
- Kunwar, A., Barik, A., Pandey, R., Priyadarsini, K.I., 2006. Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. *Biochim. Biophys. Acta.* 1760, 1513–1520.
- Kuo, M.L., Huang, T.S., Lin, J.K., 1996. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. *Biochem. Biophys. Acta.* 1317, 95–100.
- Li, L., Braiteh, F.S., Kurzrock, R., 2005. Liposome-encapsulated curcumin. In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. *Cancer* 104, 1322–1331.
- Lukita-Atmadja, W., Ito, Y., Baker, G.L., McCuskey, R.S., 2002. Effect of curcuminoids as anti-inflammatory agents on the hepatic microvascular response to endotoxin. *Shock* 17, 399–403.
- Madan, B., Ghosh, B., 2003. Diferuloylmethane inhibits neutrophil infiltration and improves survival of mice in high-dose endotoxin shock. *Shock* 19, 91–96.
- Maiti, K., Mukherjee, K., Gantait, A., Saha, B.P., Mukherjee, P.K., 2007. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. *Int. J. Pharm.* 330, 155–163.
- Motterlini, R., Foresti, R., Bassi, R., Green, C.J., 2000. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. *Free Radic. Biol. Med.* 28, 1303–1312.
- Nishinaka, Y., Aramaki, Y., Yoshida, H., Masuya, H., Sugawara, T., Ichimori, Y., 1993. A new sensitive chemiluminescence probe, L-012, for measuring the production of superoxide anion by cells. *Biochem. Biophys. Res. Commun.* 193, 554–559.
- Pan, M.N., Lin-Shiau, S.Y., Lin, J.K., 2000. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. *Biochem. Pharmacol.* 60, 1665–1676.
- Pownall, H.J., Morrisett, J.D., Gotto Jr. A.M., 1977. Composition-structure-function correlations in the binding of an apolipoprotein to phosphatidylcholine bilayer mixtures. *J. Lipid Res.* 18, 14–23.
- Pulla Reddy, A.C., Sudharshan, E., Appu Rao, A.G., Lokesh, B.R., 1999. Interaction of curcumin with human serum albumin—a spectroscopic study. *Lipids* 34, 1025–1029.
- Schmid, M.C., Varner, J.A., 2007. Myeloid cell trafficking and tumor angiogenesis. *Cancer Lett.* 250, 1–8.
- Sharma, R.A., Euden, S.A., Platton, S.L., Cooke, D.N., Shafayat, A., Hewitt, H.R., Marczylo, T.H., Morgan, B., Hemingway, D., Plummer, S.M., Pirmohamed, M., Gescher, A.J., Steward, W.P., 2004. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. *Clin. Cancer Res.* 10, 6847–6854.
- Sharma, R.A., Gescher, A.J., Steward, W.P., 2005. Curcumin: the story so far. *Eur. J. Cancer* 41, 1955–1968.
- Shishodia, S., Sethi, G., Aggarwal, B.B., 2005. Curcumin: getting back to the roots. *Ann. N.Y. Acad. Sci.* 1056, 206–217.
- Siddiqui, A.M., Cui, X., Wu, R., Dong, W., Zhou, M., Hu, M., Simms, H.H., Wang, P., 2006. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. *Crit. Care Med.* 34, 1874–1882.
- Singh, S., Aggarwal, B.B., 1995. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). *J. Biol. Chem.* 270, 24995–25000.
- Sou, K., Goins, B., Takeoka, S., Tsuchida, E., Phillips, W.T., 2007. Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo. *Biomaterials* 28, 2655–2666.
- Sou, K., Kilpper, R., Goins, B., Tsuchida, E., Phillips, W.T., 2005. Circulation kinetics and organ distribution of Hb-vesicles developed as a red blood cell substitute. *J. Pharmacol. Exp. Ther.* 312, 702–709.
- Tønnesen, H.H., 2002. Solubility, chemical and photochemical stability of curcumin in surfactant solutions. *Studies of curcumin and curcuminoids, XXVIII. Pharmazie* 57, 820–824.
- Zeisberger, S.M., Odermatt, B., Marty, C., Zehnder-Fjällman, A.H.M., Ballmer-Hofer, K., Schwendener, R.A., 2006. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. *Br. J. Cancer* 95, 272–281.

# Haemoglobin-vesicles as artificial oxygen carriers: present situation and future visions

■ H. Sakai<sup>1</sup>, K. Sou<sup>1</sup>, H. Horinouchi<sup>2</sup>, K. Kobayashi<sup>2</sup> & E. Tsuchida<sup>1</sup>

From the <sup>1</sup>Oxygen Infusion Project, Advanced Research Institute for Science and Engineering, Waseda University; and <sup>2</sup>Department of General Thoracic Surgery, School of Medicine, Keio University; Tokyo, Japan

**Abstract.** Sakai H, Sou K, Horinouchi H, Kobayashi K, Tsuchida E (Research Institute for Science and Engineering, Waseda University; and School of Medicine, Keio University; Tokyo, Japan). Haemoglobin-vesicles as artificial oxygen carriers: present situation and future visions (Review). *J Intern Med* 2008; **263**: 4–15.

During the long history of development of haemoglobin (Hb)-based O<sub>2</sub> carriers (HBOCs), many side effects of Hb molecules have become apparent. They imply the physiological importance of the cellular structure of red blood cells. Hb-vesicles (HbV) are artificial O<sub>2</sub> carriers that encapsulate concentrated Hb

solution with a thin lipid membrane. We have overcome the intrinsic issues of the suspension of HbV as a molecular assembly, such as stability for storage and in blood circulation, blood compatibility and prompt degradation in the reticuloendothelial system. Animal tests clarified the efficacy of HbV as a transfusion alternative and the possibility for other clinical applications. The results of ongoing HbV research make us confident in advancing further development of HbV, with the expectation of its eventual realization.

**Keywords:** artificial oxygen carrier, biocompatibility, liposome, nanotechnology, polyethylene glycol.

## Introduction

Since the discovery of blood type antigen by Landsteiner in 1900, allogeneic blood transfusion has developed into a routine clinical practice; it has contributed to human health and welfare. Infectious diseases such as hepatitis and HIV have become widespread social problems, but a strict virus test by nucleic acid amplification test (NAT) is extremely effective to detect trace presences of a virus to minimize infection (although it is available mainly in a few developed countries). Even so, NAT poses problems such as detection limits during a window period and limited species of viruses for testing. Emergence of new viruses (such as West Nile virus, avian influenza and Ebola) and a new type of pathogen, prions, also threaten humans throughout the world. The preservation period of donated red blood cells (RBCs) is limited to 3 weeks in Japan. Immunological responses (such as anaphylaxis and graft-versus-host disease), and

contingencies of blood type incompatibility further limit the utility of blood products. To obviate or minimize homologous transfusion, the transfusion trigger has been reconsidered, and roughly reduced from 10 to 6–8 g dL<sup>-1</sup>. Bloodless surgery and preoperational enhancement of erythropoiesis for storing autologous blood have become common. However, these epoch-making treatments are not always practical for all patients. Some developed countries with ageing populations are confronting a decreasing number of young donors and an increasing number of aged recipients. Prohibition of blood donation from people who have travelled certain countries during a specific period also exacerbates the blood shortage in Japan. On the other hand, in some developing countries, establishment of a safe blood donation system is difficult. Under such circumstances, research of blood substitutes has gathered great attention and has been developed worldwide [1–4]. In Japan, for example, the government has given strong support to development of blood



substitutes in the wake of two tragedies: infection, by AIDS, of haemophiliac patients who had received nonpasteurized plasma products and the Great Hanshin Earthquake disaster. The requisites for artificial oxygen carriers that we develop should be not only effectiveness for tissue oxygenation, but also the following:

- 1 No blood type antigen and no infection (no pathogens);
- 2 Stability for long-term storage (e.g. over 2 years) at room temperature for stockpiling for any emergency;
- 3 Low toxicity and prompt metabolism, even after massive infusion;
- 4 Physicochemical properties that are adjustable to resemble those of human blood and
- 5 Reasonable production expense and cost performance.

Realization of such an artificial oxygen carrier will revolutionize transfusion medicine.

### Physiological significance of cellular structure


Physicochemical measurements of O<sub>2</sub>-releasing behaviours have revealed that the cellular structure of RBCs might not be effective for facilitating O<sub>2</sub> releasing in comparison with a homogeneous haemoglobin (Hb) solution [5–7]. However, nature has selected this cellular structure through evolution. The reasons for Hb encapsulation in RBCs are: (i) a decrease in the high colloidal osmotic pressure of Hb; (ii) prevention of the removal of Hb from blood circulation and (iii) preservation of the chemical environment in cells, such as the concentration of phosphates (2,3-diphosphoglyceric acid (DPG), ATP, etc.) and other electrolytes. Moreover, during the long history of the development of Hb-based O<sub>2</sub> carriers (HBOCs), many side effects of Hb molecules have become apparent, such as the dissociation of tetrameric Hb subunits into two dimers ( $\alpha_2\beta_2 \rightarrow 2\alpha\beta$ ) that might induce renal toxicity, and entrapment of gaseous messenger molecules (NO and CO) inducing vasoconstriction, hypertension, reduced blood flow and tissue oxygenation at microcirculatory levels [8, 9], neurological disturbances, and the

malfunctioning of oesophageal motor function [10]. These side effects of Hb molecules imply the importance of the cellular structure (Fig. 1).


Pioneering work of Hb encapsulation to mimic the cellular structure of RBCs was performed by Chang in 1957 [1], who prepared microcapsules (5  $\mu\text{m}$ ) made of nylon, collodion, etc. Toyoda in 1965 [11] and the Kambara-Kimoto group [12] also covered Hb solutions with gelatine, gum Arabic, silicone, etc. Nevertheless, it was shown to be extremely difficult to regulate the particle size that was appropriate for blood flow in the capillaries and to obtain sufficient biocompatibility. After Bangham and Horne reported in 1964 that phospholipids assemble to form vesicles in aqueous media, and that they encapsulate water-soluble materials in their inner aqueous interior [13], it seemed reasonable to use such vesicles for Hb encapsulation. Djordjevich and Miller in 1977 prepared liposome-encapsulated Hb (LEH) composed of phospholipids, cholesterol, fatty acids, etc. [14]. In the US, Naval Research Laboratories showed remarkable progress of LEH [15].

However, some intrinsic issues of encapsulated Hbs remained, mainly related to molecular assembly and particle dispersion. What we call Hb-vesicles (HbV) with high-efficiency production processes and their improved properties, were established by Tsuchida's group [16–18] based on technologies of molecular assembly and precise analysis of pharmacological and physiological aspects (Fig. 2). The salient characteristics of HbV are the following:

- 1 Human Hb is purified completely via pasteurization at 60 °C and ultrafiltration; no viruses exist [19–21];
- 2 A concentrated Hb solution, nearly 35 g dL<sup>-1</sup>, is encapsulated with a thin bilayer membrane [16–18];
- 3 A new synthetic lipid is used to prevent platelet (PLT) activation [22, 23];
- 4 PEG-modification guarantees long-term storage over 2 years at room temperature, blood compatibility and extended circulation half-life [24–30];



**Fig. 1** What is the optimal dimension of artificial oxygen carriers? There is an upper limitation, below the capillary diameter, to prevent capillary plugging, and for the sterilization by membrane filters. On the other hand, the much smaller ones show higher rates of renal excretion and vascular wall permeabilities with side effects such as hypertension and neurological disturbances. Hb-vesicles show very low level of vascular wall permeabilities. Therefore, the Hb-vesicles seems appropriate from the viewpoint of hemodynamics. However, we have to clarify the influence of Hb-vesicles on the reticuloendothelial system (RES) because the fate of Hb-vesicles is RES trapping (see Fig. 3).



**Fig. 2** (Left) Schematic representation of Hb-vesicle (HbV). One particle contains about 30 000 Hb molecules. The surface of one HbV is modified using polyethylene glycol chains that ensure the dispersion stability of HbV during storage and during circulation in the bloodstream. (Middle) The transmission electron micrograph depicts the well-regulated particle size (250 nm) and high Hb content within the vesicles. (Right) The packed HbV suspension looks turbid, like a mixture of milk and red wine, because of light-scattering of the particle suspension.

5 The cellular structure, which resembles that of RBCs, shields all side effects of Hb molecules, such as scavenging NO and CO [8, 9, 27];

6 The particle size (250 nm) is appropriate for sterilization, circulation persistence and biodistribution [18, 28] and

7 Hb-vesicles do not show colloid osmotic pressure. Addition of a plasma substitute solution such as recombinant albumin is effective to regulate colloid osmotic pressure [31–33].

### Stabilized HbV for a long-term storage

Because Hb autoxidizes to form metHb and loses its O<sub>2</sub>-binding ability during storage as well as during blood circulation, prevention of metHb formation is necessary. Some groups have reported a method to preserve deoxygenated Hbs in the liquid state [34] using well-known intrinsic characteristics of Hb: the Hb oxidation rate in a solution is dependent on the O<sub>2</sub> partial pressure; also, deoxyHb is not autoxidized at ambient temperatures [35]. For HbV, not only the inside Hb, but also the cellular structure (liposome) must be physically stabilized to prevent intervesicular aggregation, fusion and leakage of the encapsulated Hb.

Liposomes, as molecular assemblies, have been generally inferred to be structurally unstable. Many researchers have sought to develop stabilization methods that use polymer chains [36]. Polymerization of phospholipids that contain dienoyl groups was studied extensively in our group. For example, gamma-ray irradiation induces radiolysis of water molecules and generates OH radicals that initiate intermolecular polymerization of dienoyl groups in phospholipids. This method produces enormously stable liposomes, like rubber balls, which are resistant to freeze-thawing, freeze-drying and rehydration [37–39]. However, the polymerized liposomes were so stable that they were not degraded easily in the macrophages, even 30 days after injection [40]. It was concluded that polymerized lipids would not be appropriate for intravenous injection. Subsequently, it was clarified that selection of appropriate lipids (phospholipid/cholesterol/negatively charged lipid/PEG-lipid) and their composition are important to enhance the stability of liposomes without polymerization. Surface modification of liposomes with PEG chains is sufficient for dispersion stability [24–30].

We investigated the possibility of long-term preservation of HbV through a combination of two

techniques, e.g. deoxygenation and PEG modification during storage for 2 years [24]. The PEG chains on the vesicular surface stabilize the dispersion state and prevent aggregation and fusion for 2 years because of their steric hindrance. The original metHb content (approximately 3%) before preservation decreased gradually to <1% in all samples after 1 month because of the presence of a reductant, such as homocysteine, inside the vesicles that consumed the residual O<sub>2</sub> and gradually reduced the trace amount of metHb. The rate of metHb formation was strongly dependent on the O<sub>2</sub> partial pressure: no increase in the metHb formation was observed because of the intrinsic stability of the deoxygenated Hb. In fact, the metHb content did not increase for 2 years. These results clearly indicate the possibility that the HbV suspension can be stored at room temperature for at least 2 years, which would enable stockpiling of HbV for any emergency.

### Blood compatibility of Hb-vesicles

Liposome is not a solute but a particle in a suspension. Once injected, the surface is sometimes recognized by, or interacted with blood components. The so-called 'injection reaction', or pseudo-allergy is caused by complement activation with liposomal products [41] and a perfluorocarbon emulsion. Therefore, examination of blood compatibility of liposomal particles is important for clinical use. Transient thrombocytopenia in relation to complement activation is an extremely important haematological effect observed in rodent models after infusion of LEH (containing DPPG: 1,2-dipalmitoyl-*sn*-glycero-3-phosphatidyl glycerol), developed by the Naval Research Laboratory [42, 43]. In our group, exchange transfusion with the old-type HbV (containing DPPG, no PEG modification) in anesthetized rats resulted in thrombocytopenia [31]. Similar effects were also observed for administration of negatively charged liposomes [44, 45]. The transient reduction in PLT counts caused by liposomes was also associated with sequestration of PLTs in the lung and liver. Such non-physiological PLT activation would engender initiation and modulation of inflammatory responses because PLTs contain an array of potent proinflammatory

substance. However, the present HbV apparently does not induce thrombocytopenia in animal experiments, probably because the present HbV contains PEG-modification and a different type of negatively charged lipid (DHSG: 1,5-*O*-dihexadecyl-*N*-succinyl-L-glutamate), not DPPG or a fatty acid [22, 23].

Detailed blood compatibility of HbV in relation to negatively charged lipid was examined by Dr H. Ikeda at Hokkaido Red Cross Blood Center (Sapporo) and his colleagues [22, 23, 25, 46]. The present PEG-modified HbV containing DHSG did not affect the extrinsic or intrinsic coagulation activities of human plasma, whereas HbV containing DPPG and no PEG modification tended to shorten the intrinsic coagulation time. The kallikrein-kinin cascade of the plasma was activated slightly by DPPG-HbV, but not by the present PEG-DHSG-HbV. Moreover, the complement consumption of the plasma was observed by incubation with DPPG-HbV, but not with the present PEG-DHSG-HbV. These results indicate that the present PEG-DHSG-HbV has a higher biocompatibility with human plasma. Moreover, the exposure of human PLTs to high concentrations of the present HbV (up to 40%) *in vitro* did not cause PLT activation and did not adversely affect the formation and secretion of prothrombotic substances or proinflammatory substances that are triggered by PLT agonists. These results imply that HbV, at concentrations of up to 40%, has no aberrant interactions with either unstimulated or agonist-induced PLTs.

### Biodistribution and fate of Hb-vesicles in reticuloendothelial system


The dose rate of blood substitutes would be considerably larger than those of other drugs, and their circulation time would be considerably shorter than RBC. Therefore, their biodistribution, metabolism, excretion and side effects must be characterized in detail especially about the reticuloendothelial system (RES).

Normally, free Hb released from RBC is bound rapidly to haptoglobin and is consequently removed from circulation by hepatocytes. However, when the Hb concentration is greater than the haptoglobin-binding

capacity, unbound Hb is filtered through the kidney, where it is actively absorbed. Haemoglobinuria and eventual renal failure occur when the reabsorption capacity of the kidney is exceeded. The encapsulation of Hb in vesicles completely suppresses renal excretion. However, HbV in the bloodstream is ultimately captured by phagocytes in the RES (or mononuclear phagocytic system) in much the same manner as senescent RBC are, as confirmed by radioisotope <sup>99m</sup>Tc-labelled HbV injection [15, 28]. Gamma camera images of <sup>99m</sup>Tc-HbV showed that HbV remains in the bloodstream immediately after infusion so that the heart and liver that contain much blood showed strong intensity (Fig. 3a). However, HbV are finally distributed mainly in the liver, spleen and bone marrow. The circulation half-life is dose dependent; when the dose rate was 14 mL kg<sup>-1</sup>, the circulation half-life was 32 h. The circulation time in the case of the human body can be estimated as twice or three times longer; or about 2 or 3 days at the same dose rate.

The time course of liver uptake was monitored using a confocal fluorescence microscope after fluorescence-labelled HbV was infused intravenously in an anesthetized hamster. Even though the individual particles of HbV were indistinguishable, they are recognizable with strong fluorescence when HbV are accumulated in phagosomes of Kupffer cells (Fig. 3b). Transmission electron microscopy (TEM) of the spleen 1 day after infusion of HbV clearly demonstrated the presence of HbV particles in macrophages, where HbV particles that appear as black dots are captured by the phagosomes [47] (Fig. 3c). However, after 7 days, the HbV structure cannot be observed. We confirmed transient splenomegaly with no irreversible damage to the organs and complete metabolism within a week. Immunochemical staining with a polyclonal anti-human Hb antibody was used as the marker of Hb in the HbV, and clarified that HbV almost disappeared after 7 days in both the spleen and liver (Fig. 3d) [47].

During metabolism of Hb, bilirubin and iron would be released. However, in our animal experiments of topload infusion, daily repeated infusions, and 40% blood exchange, neither of those products increased



**Fig. 3** Biodistribution and fate of Hb-vesicle (HbV). (a) Gamma-camera images of the distribution of <sup>99m</sup>Tc-labelled HbV in rats. At 3 h after injection, the heart and the liver showed a strong intensity because of the large blood volume. However, 24 h later, the intensity increased in the liver and spleen, the so-called reticuloendothelial system. (b) The liver surface of an anesthetized golden hamster 40 min after injection of fluorescence-labelled HbV observed using laser confocal scanning microscopy. The individual HbV particles flowing in the sinusoid are not detected, but the strong fluorescence is observed only in the Kupffer cells when they phagocyte HbV. (c) Transmission electron micrograph of rat spleen 1 day after intravenous injection of HbV. The small black dots are HbV near red blood cell in the capillaries and in the phagosomes of spleen macrophages. They disappear completely within 1 week. (d) Staining with anti-human Hb antibody revealed the presence of HbV in the liver Kupffer cells and sinusoids 1 day after infusion. However, they disappear within 1 week.

in the plasma within 14 days [33, 48, 49]. The released haeme from Hb in HbV might be metabolized by the inducible form of haeme oxygenase-1 in the Kupffer cells of the liver and the spleen macrophages. Bilirubin would normally be excreted in the bile as a normal pathway, and no obstruction or stasis of the bile should occur in the biliary tree. Berlin blue staining revealed considerable deposition of haemosiderin in the liver and spleen, even after 14 days. Normally, iron from a haeme is stored in the ferritin molecule. Both ferritin and haemosiderin release iron. They are anticipated to induce hydroxyl radical production followed by lipid peroxidation. The iron release rate from haemosiderin, however, is substantially less than that from ferritin.

Consequently, the excess amount of iron would then normally be stored in an insoluble and less toxic form as haemosiderin. Hemosiderosis often occurs in patients who have received repeated blood transfusions because of the shorter half-life of the stored RBCs. Moderate splenomegaly and haemosiderin deposition were also confirmed in the spleen after injection of stored RBCs, partly because of the accumulation and degradation of stored RBCs with the lowered membrane deformability and shortened circulation half-life [33, 50].

As for the membrane components of HbVs, it was reported that the infused lipid components of


liposomes are entrapped in the Kupffer cells, and that phospholipid is metabolized and reused as a component of the cell membrane, or excreted in bile, especially as fatty acids and CO<sub>2</sub> in exhaled air. It was recently clarified using a <sup>3</sup>H-cholesterol that cholesterol of HbV is released from macrophages to blood, and is ultimately excreted in faeces. The PEG chain is widely used for surface modification of liposomal products. The chemical crosslinker of PEG-lipid is susceptible to hydrolysis to release PEG chains during metabolism. The released PEG chains, which are

known as inert macromolecules, should be excreted in urine through the kidneys [51].

More precise data are necessary. However, these results imply that the metabolism of HbV and the excretion are within the physiological capacity that has been well characterized for the metabolism of senescent RBCs and conventional liposomal products.

### Rheological properties and efficacy of an Hb-vesicle suspension as a transfusion alternative

A single HbV particle (approximately 250 nm diameter) contains about 30 000 Hb molecules. The HbV is much smaller than RBC, PLT or white blood cell (WBC) particles (Fig. 4a). Nevertheless, HbV acts as a particle in the blood and not as a solute; the colloid osmotic pressure of the HbV suspension is nearly zero. Addition of a plasma expander is necessary for a large substitution of blood to maintain the blood volume. The plasma expander candidates are human serum albumin (HSA), hydroxyethyl starch, dextran or gelatine, depending on the clinical setting, cost, country and clinician. Recombinant human serum albumin (rHSA) is an alternative [32, 33]. The impossibility of transmission of any infectious disease from humans is the greatest advantage of rHSA, which will soon be approved for clinical use in Japan [52].



**Fig. 4** How small is Hb-vesicle (HbV)? (a) The transmittance electron micrograph of rat blood 1 day after infusion of HbV. The buffy coat, obtained by a centrifugation of blood, was fixed using a 2.5% glutaraldehyde solution. Many HbV particles are visible in the red circles. They are much smaller than red blood cell (RBC), WBCs or PLT. (b) Flow patterns of the mixture of HbV and RBC suspended in recombinant human serum albumin in a narrow tube (center-line flow velocity: 1 mm s<sup>-1</sup>). From left to right, the mixing ratios, RBC/HbV by volume are 100/0, 50/50 and 10/90 at a constant (Hb) = 10 g dL<sup>-1</sup>. The RBCs tend to flow in the centerline, whereas HbV particles are dispersed homogeneously in a suspension medium. (c) Micrograph of a hamster skin microvasculature after 80% exchange transfusion with HbV suspended in 5% HSA solution, with an illumination with a wavelength of about 420 nm, being absorbed at the *Soret* band of Hb in HbV and RBC. The capillaries are blackened because of the homogeneous dispersion of HbV in the plasma phase. This homogeneous distribution believed to be effective for tissue oxygenation.

The rheological property of an artificial oxygen carrier is important because the infusion amount should be considerably large, which might affect the blood viscosity and hemodynamics. The viscosity of HbV suspended in 5%-rHSA was similar with that of blood, and the mixtures with RBC at various mixing ratios showed viscosities of 3–4 cP [53]. The main component to determine blood viscosity is RBC; the results indicate no great interaction between HbV and RBC. To observe the flow pattern of the mixture of HbV and RBC, they were mixed in various volume ratios. Then the suspension was perfused through an O<sub>2</sub>-permeable narrow tube (28 μm inner diameter) and exposed to a deoxygenated environment [6]. Because HbV was dispersed homogeneously in the rHSA solution, increasing the volume of the HbV suspension thickened the marginal RBC-free layer and the plasma phase became semitransparent (Fig. 4b). The measurement of the O<sub>2</sub>-release rate showed that HbV releases O<sub>2</sub> similarly to RBCs. On the other hand, an acellular Hb solution, in a comparative study, showed the facilitated O<sub>2</sub>-release attributable to the effect of diffusion of small HbO<sub>2</sub>. The slow O<sub>2</sub>-release rate of HbV, which resembles that of RBC, is important to prevent autoregulatory vasoconstriction. Microvascular observation after 80% exchange transfusion with HbV suspended in HSA in conscious hamsters with a dorsal skin-fold window model of Prof. Intaglietta (UCSD) also showed that HbV was distributed homogeneously in the plasma phase; the capillary shape was visualized (Fig. 4c). This homogeneous distribution is inferred to be effective for improved blood flow and homogeneous tissue oxygenation.

Extensive *in vivo* studies of such HbV suspended in plasma-derived HSA or rHSA revealed sufficient O<sub>2</sub> transporting efficiency that is apparently comparable to RBCs in extreme blood exchange experiments [29–31, 33, 54–56] and fluid resuscitation from hemorrhagic shock [32, 57–60]. It was confirmed in rat models that haematopoietic activity was preserved and the decreased haematocrit returned to the original level within 1 or 2 weeks, whilst HbV captured in RES disappeared completely [33]. A recent experiment of HbV suspended in rHSA as a priming solution for cardiopulmonary bypass (CPB) in a rat model

showed that HbV protects neurocognitive function by transporting O<sub>2</sub> to brain tissue even when the haematocrit is reduced markedly [61]. Homologous blood use is considered to be the gold standard for CPB priming in infants despite exposure of patients to potential cellular and humoral antigens. However, the results indicate that the use of HbV for CPB priming might prevent neurocognitive decline in infants because of considerable hemodilution. Other studies investigating HbV suspension as a possible perfusate for organ transplantation are also underway for the heart, liver, intestine, etc.

### New concepts to design HbV

Development of artificial O<sub>2</sub> carriers was initiated originally with a simple idea and an expectation that the materials that bind or dissolve O<sub>2</sub> can behave similarly to RBCs in the bloodstream. Unfortunately, it was not so simple. During its long history of development, unexpected side effects were clarified such as capillary plugging, renal toxicity, vasoconstriction, vascular injury and accumulation. Decades-long R&D of artificial O<sub>2</sub> carriers has yielded no commercially available material for clinical use in Europe, Japan or the US. Recent advanced biotechnology enables *ex vivo* RBC production from haematopoietic stem cells [62]. However, problems remain of large-scale production and long-term storage for stockpiling. On the other hand, no doubts persist about the strong demand and expectation of a blood substitute.

The importance of the sophisticated function of RBCs in concert with vascular physiology has been clarified. New concepts are proposed in terms of the physicochemical properties of Hb-based artificial O<sub>2</sub> carriers. Historically, it has been regarded that the O<sub>2</sub> affinity is regulated similarly to RBCs (25–30 torr). Theoretically, this enables sufficient O<sub>2</sub> unloading during blood microcirculation, as can be evaluated according to the arterio-venous difference in O<sub>2</sub> saturation in accordance with an O<sub>2</sub> equilibrium curve. It has been expected that decreasing O<sub>2</sub> affinity (increasing P<sub>50</sub>) increases O<sub>2</sub> unloading. However, this concept is controversial in light of recent findings because an excess O<sub>2</sub> supply would cause autoregulatory vasoconstriction

and microcirculatory disorders. A new conceptualization is that HBOCs with a high O<sub>2</sub> affinity (low P<sub>50</sub>) retain O<sub>2</sub> in the upstream artery or arteriole and release O<sub>2</sub> in the capillaries of the targeted tissue. This hypothesis has been supported recently by results of PEG-modified Hbs and HbV by microcirculatory observations [55, 56, 63, 64]. The P<sub>50</sub> of HbV is easily regulated by manipulating the content of an allosteric effector, pyridoxal 5'-phosphate (PLP), inside the HbV [55, 65]. For example, equimolar PLP to Hb (PLP/Hb = 1/1 by mol) was coencapsulated, and P<sub>50</sub> was regulated to 18 torr. When the molar ratio PLP/Hb was 3/1, P<sub>50</sub> was regulated to 32 torr. The present HbV contains PLP at PLP/Hb = 2.5 by mol; the resulting P<sub>50</sub> is about 25–28 torr, which shows sufficient O<sub>2</sub> transporting capacity as a transfusion alternative for extreme hemodilution, resuscitative fluid for hemorrhagic shock and prime solution for extracorporeal circulation. The P<sub>50</sub> of HbV without PLP and Cl<sup>-</sup> is 8–9 torr.

Because infusion of an artificial O<sub>2</sub> carrier necessitates the substitution of a large volume of blood, its impact on hemorheology is remarkable. It has been regarded that lower blood viscosity after hemodilution is effective for tissue perfusion. However, microcirculatory observation shows that, in some cases, lower viscosity decreases shear stress on the vascular wall, engendering vasoconstriction and reduced functional capillary density [66]. Therefore, an appropriate viscosity might exist, which maintains the normal tissue perfusion level. A large molecular dimension such as HbV can provide viscous fluids. In relation to this, our recent studies clarified that HbV suspended a series of plasma substitutes can provide non-Newtonian viscous fluid without capillary plugging [67]. A large molecular dimension is also effective to reduce vascular permeability and to minimize the reaction with NO and CO as vasorelaxation factors. These new concepts suggest reconsideration of the design of artificial O<sub>2</sub> carriers [68]. Actually, new products are appearing, although they are in the preclinical stage, not only HbV, but also zero-link polymerized Hb [69] and others with larger molecular dimensions and higher O<sub>2</sub> affinities. Ermi *et al.* clarified that HbV with a high O<sub>2</sub> affinity (low P<sub>50</sub>, such as 9–15 torr) and high

viscosity (such as 11 cP) suspended in a high-molecular-weight HES solution was effective for oxygenation of an ischaemic skin flap [63, 70–72]. That study showed that HbV would retain O<sub>2</sub> in the upper arterioles, then perfuse through collateral arteries and deliver O<sub>2</sub> to the targeted ischaemic tissues. The results imply the further application of HbV for other ischaemic diseases such as myocardial and brain infarction and stroke.

### Concluding remarks

Advantages of artificial O<sub>2</sub> carriers including HbV are the absence of blood-type antigens and infectious viruses, along with stability for a long-term storage for any emergency that might overwhelm the RBC transfusion capacity. The shorter half-lives of the HbV in the bloodstream (2–3 days) limit their use, but they are applicable as a transfusion alternative for shorter periods of use. Easy manipulation of physicochemical properties of HbV supports the possible tailor-made O<sub>2</sub> carriers that suit various clinical indications. The achievements of ongoing HbV research described above make us confident in advancing further development of HbV, with the expectation of its eventual realization.

### Conflicts of interest statement

Among the authors, ET, HS, KS and KK are consultants of Oxygenix Inc. (Tokyo, Japan).

### Acknowledgements

This work was partly supported by Health Sciences Research Grants (Research on Regulatory Science), the Ministry of Health, Labour and Welfare, Japan. The authors gratefully acknowledge Prof. S. Takeoka (Waseda University); Prof. Yozu, Prof. Suematsu, Dr M. Watanabe, Dr Y. Izumi, Dr M. Yamamoto, Dr T. Ikeda, Dr E. Ikeda (Keio University); Dr H. Ikeda, Dr H. Azuma, Dr M. Fujiwara, Dr H. Abe (Hokkaido Red Cross Blood Center); Dr M. Takaori (Higashitakarazuka Satoh Hospital); Prof. M. Otagiri, Dr M. Anraku (Kumamoto University); Prof. N. Maeda, Dr Y. Suzuki (Ehime University); Prof. M. Intaglietta,



Dr A.G. Tsai, Dr P. Cabrales (University of California, San Diego); Prof. W.T. Phillips (University of Texas, San Antonio); Prof. D. Ermi (Inselspital Hospital, University of Berne) and their active colleagues for meaningful discussions and contributions to this research.

## References

- 1 Chang TMS. *Blood Substitutes; Principles, Methods, Products, and Clinical Trials*. Basel: Karger, 1997.
- 2 Tsuchida E, ed. *Blood Substitutes: Present and Future Perspectives*. Amsterdam: Elsevier, 1998.
- 3 Kobayashi K, Tsuchida E, Horinouchi H, eds. *Artificial Oxygen Carrier: its Front Line, Keio University International Symposia for Life Sciences and Medicine*, Vol. 12. Tokyo: Springer-Verlag, 2005.
- 4 Winslow R, ed. *Blood Substitutes*, Amsterdam: Elsevier, 2006.
- 5 Page TC, Light WR, McKay CB, Hellums JD. Oxygen transport by erythrocyte/hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobin-based oxygen carrier performance. *Microvasc Res* 1998; 55: 54–66.
- 6 Sakai H, Suzuki Y, Kinoshita M, Takeoka S, Maeda N, Tsuchida E. O<sub>2</sub> release from Hb vesicles evaluated using an artificial, narrow O<sub>2</sub>-permeable tube: comparison with RBCs and acellular Hbs. *Am J Physiol Heart Circ Physiol* 2003; 285: H2543–55.
- 7 Vandegriff KD, Olson JS. The kinetics of O<sub>2</sub> release by human red blood cells in the presence of external sodium dithionite. *J Biol Chem* 1984; 259: 12609–18.
- 8 Goda N, Suzuki K, Naito M *et al.* Distribution of heme oxygenase isoforms in rat liver. Topographic basis for carbon monoxide-mediated microvascular relaxation. *J Clin Invest* 1998; 101: 604–12.
- 9 Sakai H, Hara H, Yuasa M *et al.* Molecular dimensions of Hb-based O<sub>2</sub> carriers determine constriction of resistance arteries and hypertension. *Am J Physiol Heart Circ Physiol* 2000; 279: H908–15.
- 10 Murray JA, Ledlow A, Launspach J, Evans D, Loveday M, Conklin JL. The effects of recombinant human hemoglobin on esophageal motor function in humans. *Gastroenterology* 1995; 109: 1241–8.
- 11 Toyoda T. Artificial blood. *Kagaku* 1965; 35: 7–13 (in Japanese).
- 12 Kimoto S, Hori M, Toyoda T, Sekiguchi W. Artificial red cells. *Gekachiryou (Surg Ther)* 1968; 19: 324–32 (in Japanese).
- 13 Bangham AD, Home RW. Negative staining of phospholipids and their structure modification by surface-active agents as observed in the electron microscope. *J Mol Biol* 1964; 8: 660–8.
- 14 Djordjevich L, Miller IF. Lipid encapsulated hemoglobin as a synthetic erythrocyte. *Fed Proc* 1977; 36: 567.
- 15 Rudolph AS, Klipper RW, Goins B, Phillips WT. In vivo bio-distribution of a radiolabeled blood substitute: <sup>99m</sup>Tc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. *Proc Natl Acad Sci U S A* 1991; 88: 10976–80.
- 16 Sakai H, Hamada K, Takeoka S, Nishide H, Tsuchida E. Physical properties of hemoglobin vesicles as red cell substitutes. *Biotechnol Prog* 1996; 12: 119–25.
- 17 Takeoka S, Ohgushi T, Terase K, Ohmori T, Tsuchida E. Layer-controlled hemoglobin vesicles by interaction of hemoglobin with a phospholipid assembly. *Langmuir* 1996; 12: 1755–9.
- 18 Sou K, Naito Y, Endo T, Takeoka S, Tsuchida E. Effective encapsulation of proteins into size-controlled phospholipid vesicles using freeze-thawing and extrusion. *Biotechnol Prog* 2003; 19: 1547–52.
- 19 Sakai H, Takeoka S, Yokohama H, Seino Y, Nishide H, Tsuchida E. Purification of concentrated Hb using organic solvent and heat treatment. *Protein Expr Purif* 1993; 4: 563–9.
- 20 Naito Y, Fukutomi I, Masada Y *et al.* Virus removal from hemoglobin solution using Planova membrane. *J Artif Organs* 2002; 5: 141–5.
- 21 Abe H, Ikebuchi K, Hirayama J *et al.* Virus inactivation in hemoglobin solution by heat treatment. *Artif Cells Blood Substit Immobil Biotechnol* 2001; 29: 381–8.
- 22 Abe H, Fujihara M, Azuma H *et al.* Interaction of hemoglobin vesicles, a cellular-type artificial oxygen carrier, with human plasma: effects on coagulation, kallikrein-kinin, and complement systems. *Artif Cells Blood Substit Immobil Biotechnol* 2006; 34: 1–10.
- 23 Wakamoto S, Fujihara M, Abe H *et al.* Effects of hemoglobin vesicles on resting and agonist-stimulated human platelets in vitro. *Artif Cells Blood Substit Immobil Biotechnol* 2005; 33: 101–11.
- 24 Sakai H, Tomiyama K, Sou K, Takeoka S, Tsuchida E. Poly(ethylene glycol)-conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state. *Bioconjug Chem* 2000; 11: 425–32.
- 25 Wakamoto S, Fujihara M, Abe H *et al.* Effects of poly(ethylene-glycol)-modified hemoglobin vesicles on agonist-induced platelet aggregation and RANTES release in vitro. *Artif Cells Blood Substit Immobil Biotechnol* 2001; 29: 191–201.
- 26 Sou K, Endo T, Takeoka S, Tsuchida E. Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. *Bioconjug Chem* 2000; 11: 372–9.
- 27 Nakai K, Usuba A, Ohta T *et al.* Coronary vascular bed perfusion with a polyethylene glycol-modified hemoglobin-encapsulated liposome, neo red cell, in rats. *Artif Organs* 1998; 22: 320–5.
- 28 Sou K, Klipper R, Goins B, Tsuchida E, Phillips WT. Circulation kinetics and organ distribution of Hb-vesicles developed as a red blood cell substitute. *J Pharmacol Exp Ther* 2005; 312: 702–9.
- 29 Sakai H, Takeoka S, Park SI *et al.* Surface-modification of hemoglobin vesicles with poly(ethylene glycol) and effects on aggregation, viscosity, and blood flow during 90%-exchange transfusion in anesthetized rats. *Bioconjug Chem* 1997; 8: 23–30.

- 30 Sakai H, Tsai AG, Kerger H *et al.* Subcutaneous microvascular responses to hemodilution with red cell substitutes consisting of polyethylene glycol-modified vesicles encapsulating hemoglobin. *J Biomed Mater Res* 1998; 40: 66–78.
- 31 Izumi Y, Sakai H, Takeoka S *et al.* Evaluation of the capabilities of a hemoglobin vesicle as an artificial oxygen carrier in a rat exchange transfusion model. *ASAIO J* 1997; 43: 289–97.
- 32 Sakai H, Horinouchi H, Masada Y *et al.* Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. *Crit Care Med* 2004; 32: 539–45.
- 33 Sakai H, Horinouchi H, Yamamoto M *et al.* Acute 40 percent exchange-transfusion with hemoglobin-vesicles (HbV) suspended in recombinant human serum albumin solution: degradation of HbV and erythropoiesis in a rat spleen for 2 weeks. *Transfusion* 2006; 46: 339–47.
- 34 Kerwin BA, Akers MJ, Apostol I *et al.* Acute and long-term stability studies of deoxy hemoglobin and characterization of ascorbate-induced modifications. *J Pharm Sci* 1999; 88: 79–88.
- 35 Levy A, Zhang L, Rifkind JM. Hemoglobin: a source of superoxide radical under hypoxic conditions. *Oxy-radicals Mol Pathol Proc Upjohn-UCLA Symp* 1988: 11–25.
- 36 Ringsdorf H, Schlarb B, Venzmer J. Molecular architecture and function of polymeric oriented systems – models for the study of organization, surface recognition, and dynamics of biomembranes. *Angew Chem Int Ed* 1988; 27: 113–58.
- 37 Tsuchida E, Hasegawa E, Kimura N, Hatashita M, Makino C. Polymerization of unsaturated phospholipids as large unilamellar liposomes at low-temperature. *Macromolecules* 1992; 25: 2007–212.
- 38 Sakai H, Takeoka S, Yokohama H, Nishide H, Tsuchida E. Encapsulation of Hb into unsaturated lipid vesicles and gamma-ray polymerization. *Polym Adv Technol* 1992; 3: 389–94.
- 39 Akama K, Gong WL, Wang L, Tokuyama S, Tsuchida E. Stable preservation of hemoglobin vesicles as a blood substitute. *Polym Adv Technol* 1999; 10: 293–8.
- 40 Akama K, Awai K, Yano Y, Tokuyama S, Nakano Y. In vitro and in vivo stability of polymerized mixed liposomes composed of 2,4-octadecadienoyl groups of phospholipids. *Polym Adv Technol* 2000; 11: 280–7.
- 41 Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. *Toxicology* 2005; 216: 106–21.
- 42 Rabinovici R, Rudolph AS, Yue TL, Feuerstein G. Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist. *Circ Shock* 1990; 31: 431–45.
- 43 Phillips WT, Klipper R, Fresne D, Rudolph AS, Javors M, Goins B. Platelet reactivity with liposome-encapsulated hemoglobin in the rat. *Exp Hematol* 1997; 25: 1347–56.
- 44 Loughrey HC, Bally MB, Reinish LW, Cullis PR. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. *Thromb Haemost* 1990; 64: 172–6.
- 45 Doerschuk CM, Gie RP, Bally MB, Cullis PR, Reinish LW. Platelet distribution in rabbits following infusion of liposomes. *Thromb Haemost* 1989; 61: 392–6.
- 46 Abe H, Azuma H, Yamaguchi M *et al.* Effects of hemoglobin-vesicles, a liposomal artificial oxygen carrier, on hematological responses, complement and anaphylactic reactions in rats. *Artif Cells Blood Substit Immobil Biotechnol* 2007; 35: 157–72.
- 47 Sakai H, Horinouchi H, Tomiyama K *et al.* Hemoglobin-vesicles as oxygen carriers: influence on phagocytic activity and histopathological changes in reticuloendothelial system. *Am J Pathol* 2001; 159: 1079–88.
- 48 Sakai H, Horinouchi H, Masada Y, Takeoka S, Kobayashi K, Tsuchida E. Metabolism of hemoglobin-vesicles (artificial oxygen carriers) and their influence on organ functions in a rat model. *Biomaterials* 2004; 25: 4317–25.
- 49 Sakai H, Masada Y, Horinouchi H *et al.* Physiologic capacity of reticuloendothelial system for degradation of hemoglobin-vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days. *J Pharmacol Exp Ther* 2004; 311: 874–84.
- 50 Bennett GD, Kay MM. Homeostatic removal of senescent murine erythrocytes by splenic macrophages. *Exp Hematol* 1981; 9: 297–307.
- 51 Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. *J Pharm Sci* 1994; 83: 601–6.
- 52 Kobayashi K. Summary of recombinant human serum albumin development. *Biologicals* 2006; 34: 55–9.
- 53 Sakai H, Yuasa M, Onuma H, Takeoka S, Tsuchida E. Synthesis and physicochemical characterization of a series of hemoglobin-based oxygen carriers: objective comparison between cellular and acellular types. *Bioconjug Chem* 2000; 11: 56–64.
- 54 Izumi Y, Sakai H, Hamada K *et al.* Physiologic responses to exchange transfusion with hemoglobin-vesicles as an artificial oxygen carrier in anesthetized rats: changes in mean arterial pressure and renal cortical oxygen tension. *Crit Care Med* 1996; 24: 1869–73.
- 55 Sakai H, Tsai AG, Rohlfes RJ *et al.* Microvascular responses to hemodilution with Hb-vesicles as red cell substitutes: influences of O<sub>2</sub> affinity. *Am J Physiol Heart Circ Physiol* 1999; 276: H553–62.
- 56 Cabrales P, Sakai H, Tsai AG, Takeoka S, Tsuchida E, Intaglietta M. Oxygen transport by low and normal oxygen affinity hemoglobin vesicles in extreme hemodilution. *Am J Physiol Heart Circ Physiol* 2005; 288: H1885–92.
- 57 Sakai H, Takeoka S, Wettstein R, Tsai AG, Intaglietta M, Tsuchida E. Systemic and microvascular responses to the hemorrhagic shock and resuscitation with Hb-vesicles. *Am J Physiol Heart Circ Physiol* 2002; 283: H1191–9.
- 58 Yoshizu A, Izumi Y, Park SI *et al.* Hemorrhagic shock resuscitation with an artificial oxygen carrier hemoglobin-vesicle (HbV) maintains intestinal perfusion and suppresses the increase in plasma necrosis factor alpha (TNF $\alpha$ ). *ASAIO J* 2004; 50: 458–63.
- 59 Terajima K, Tsueshita T, Sakamoto A, Ogawa R. Fluid resuscitation with hemoglobin vesicles in a rabbit model of acute hemorrhagic shock. *Shock* 2006; 25: 184–9.

- 60 Goto Y, Terajima K, Tsueshita T *et al.* Fluid resuscitation with hemoglobin-vesicle solution does not increase hypoxia or inflammatory responses in moderate hemorrhagic shock. *Biomed Res* 2006; 27: 283–8.
- 61 Yamazaki M, Aeba R, Yozu R, Kobayashi K. Use of hemoglobin vesicles during cardiopulmonary bypass priming prevents neurocognitive decline in rats. *Circulation* 2006; 1(Suppl.): 1220–5.
- 62 Giarratana MC, Kobari L, Lapillonne H *et al.* Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. *Nat Biotechnol* 2005; 23: 69–74.
- 63 Plock JA, Contaldo C, Sakai H *et al.* Is the Hb in Hb vesicles infused for isovolemic hemodilution necessary to improve oxygenation in critically ischemic hamster skin? *Am J Physiol Heart Circ Physiol* 2005; 289: H2624–31.
- 64 Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O<sub>2</sub> delivery by low-P<sub>50</sub> hemoglobin: a new basis for O<sub>2</sub> therapeutics. *Am J Physiol Heart Circ Physiol* 2003; 285: H1411–9.
- 65 Wang L, Morizawa K, Tokuyama S, Satoh T, Tsuchida E. Modulation of oxygen-carrying capacity of artificial red cells (ARC). *Polym Adv Technol* 1992; 4: 8–11.
- 66 Tsai AG, Friesenecker B, McCarthy M, Sakai H, Intaglietta M. Plasma viscosity regulates capillary perfusion during extreme hemodilution in hamster skinfold model. *Am J Physiol* 1998; 275: H2170–80.
- 67 Sakai H, Sato A, Takeoka S, Tsuchida E. Rheological property of hemoglobin-vesicles (artificial oxygen carriers) suspended in a series of plasma substitute aqueous solutions. *Langmuir* 2007; 23: 8121–8.
- 68 Intaglietta M, Cabrales P, Tsai AG. Microvascular perspective of oxygen-carrying and -noncarrying blood substitutes. *Annu Rev Biomed Eng* 2006; 8: 289–321.
- 69 Matheson B, Kwansa HE, Bucci E, Rebel A, Koehler RC. Vascular response to infusions of a nonextravasating hemoglobin polymer. *J Appl Physiol* 2002; 93: 1479–86.
- 70 Contaldo C, Plock J, Sakai H *et al.* New generation of hemoglobin-based oxygen carriers evaluated for oxygenation of critically ischemic hamster flap tissue. *Crit Care Med* 2005; 33: 806–12.
- 71 Contaldo C, Schramm S, Wettstein R *et al.* Improved oxygenation in ischemic hamster flap tissue is correlated with increasing hemodilution with Hb vesicles and their O<sub>2</sub> affinity. *Am J Physiol Heart Circ Physiol* 2003; 285: H1140–7.
- 72 Erni D, Wettstein R, Schramm S *et al.* Normovolemic hemodilution with Hb vesicle solution attenuates hypoxia in ischemic hamster flap tissue. *Am J Physiol Heart Circ Physiol* 2003; 284: H1702–9.

*Correspondence:* Prof. Eishun Tsuchida, Oxygen Infusion Project, Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan.

(fax: +81 3 3205 4740; e-mail: eishun@waseda.jp)■

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

Biochimica et Biophysica Acta xx (2008) xxx–xxx

 Biochimica et Biophysica Acta  
**BBA**
[www.elsevier.com/locate/bbamem](http://www.elsevier.com/locate/bbamem)

# Electrostatic interactions and complement activation on the surface of phospholipid vesicle containing acidic lipids: Effect of the structure of acidic groups

Keitaro Sou, Eishun Tsuchida \*

Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan

Received 5 September 2007; received in revised form 22 November 2007; accepted 7 January 2008

## Abstract

Anionic vesicles containing acidic phospholipids are known complement activators. To clarify which negative physicochemical electrostatic charges on vesicles and structural specificities of acidic lipids are critical to complement activation, the electrostatic properties and activity to complement of two anionic vesicles modified with a carboxylic acid derivative or a conventional acidic phospholipid were compared. Electrophoretic mobility measurements indicated that the negative zeta potential and the electrostatic interactivity of these two anionic vesicles were equal at pH 7.4. However, the infusion of vesicles containing acidic phospholipid induced significant complement activation, while vesicles containing the carboxylic acid derivative failed to activate complement. These results indicate that the negative charge on the surface of vesicles is not critical for the activation complement, suggesting that complement activation is specific to the structure of acidic groups. This finding is likely to be important to the design of anionic biointerfaces and may support the promising medical applications of this anionic vesicle modified with a carboxylic acid derivative.

© 2008 Elsevier B.V. All rights reserved.

**Keywords:** Liposome; Acidic lipid; Anionic surface; Electrostatic interaction; Complement activation

## 1. Introduction

Anionic vesicles (liposomes), commonly formulated by mixing acidic phospholipids such as phosphoglycerol, phosphoserin, phosphoinositol, phosphatidic acid, cardiolipin, and poly(ethylene glycol) (PEG) conjugated phosphoethanolamine in lipid components are known to mediate complement activation [1–5]. Complement activation, which is followed by systemic immune activation and anaphylaxis shock, is regarded as a critical problem in the clinical setting of various biomaterials. The C1q subcomponent of C1 has a highly cationic region in residues 14–26 of the C1qA polypeptide chain, and this specific region of the collagenous stalk of C1q has been identified as being involved in interactions with negatively charged activators [5–8]. It is

believed that the antibody-independent binding of C1q to the negatively charged surface of vesicles initiates the activation of the complement cascade via the classical complement pathway [2]. To prevent complement activation, the acidic phospholipids can be removed or their negative charge can be protected by chemical modification [2,4]. It has also been reported that surface modification with a dense PEG layer is effective for preventing complement activation by covering the surface charge [9].

Our group has developed phospholipid vesicles called hemoglobin-vesicles that encapsulate human hemoglobin and that can be used as a substitute for red blood cells and as an alternative to conventional transfusion [10–14]. To achieve this challenging application of vesicles, we had to develop anionic vesicles capable of encapsulating hemoglobin using a minimum amount of lipids, retaining the negative charge on the membrane which reduces the lamellarity of vesicles and is required for improving encapsulation capacity [11–13]. Several acidic lipids have been tested and a carboxylic acid derivative, L-glutamic 53

\* Corresponding author. Tel.: +81 3 5286 3120; fax: +81 3 3205 4740.

E-mail addresses: [ksou@waseda.jp](mailto:ksou@waseda.jp) (K. Sou), [eishun@waseda.jp](mailto:eishun@waseda.jp) (E. Tsuchida).